Seikagaku Corporation · TSE:4548
Seikagaku — Q3 FY2023 Earnings Presentation
16 slides from Seikagaku's earnings presentation, Feb 14, 2024
Slide 1: Financial Results for the 3rd Quarter of Fiscal Year 2023
Exploring the Innovative Promise of Glycoscience Financial Results for the 3rd Quarter of Fiscal Year 2023 （TSE：4548）
Slide 2: Contents
Exploring the Innovative Promise of Glycoscience Contents 3Q Results P3 Research and Development P10 Net Sales P3-7 SI-6603 P11 (Lumbar disc herniation) Income P8 SI-614 (Dry Eye) P12 Trend in R&D Expenses P9 SI-722 P13 (Interstitial cystitis and bladder pain syndrome) SI-449 (Adhesion Barrier) P14
Slide 3: Overview for 3Q of FY 2023
Exploring the Innovative Promise of Glycoscience Overview for 3Q of FY 2023 (Reference) Year-on-Year FY2023 Forecasts (8th Nov) 3Q FY2023 Results Change % of Change FY 2023 Degree of (Millions of Yen) Forecasts Progress Net sales 27,384 +1,221 +4.7% 36,100 75.9% Operating Income 2,328 -1,078 -31.6%
Slide 4: Net sales by Business Segment (3Q of FY2023)
Exploring the Innovative Promise of Glycoscience Net sales by Business Segment (3Q of FY2023) 3Q FY2023 Year-on- % of Domestic Pharmaceuticals (Millions of Yen) Results Year Change ▶ ARTZ（Joint-function improving agent） Net sales 27,384 +1,221 +4.7% • Seikagaku sales up on higher shipment volume, de
Slide 5: Net sales by Business Segment (3Q of FY2023)
Exploring the Innovative Promise of Glycoscience Net sales by Business Segment (3Q of FY2023) 3Q FY2023 Year-on- % of Domestic Pharmaceuticals (Millions of Yen) Results Year Change ▶ OPEGAN series（Ophthalmic viscoelastic devices） • Seikagaku sales up on higher shipments, Net sales 27,384 +1,221 +4.7
Slide 6: Net sales by Business Segment (3Q of FY2023)
Exploring the Innovative Promise of Glycoscience Net sales by Business Segment (3Q of FY2023) 3Q FY2023 Year-on- % of Overseas Pharmaceuticals (Millions of Yen) Results Year Change *Foreign exchange impact on Overseas Pharmaceuticals: approx. +510million yen Net sales 27,384 +1,221 +4.7% ▶ Gel-One i
Slide 7: Net sales by Business Segment (3Q of FY2023)
Exploring the Innovative Promise of Glycoscience Net sales by Business Segment (3Q of FY2023) 3Q FY2023 Year-on- % of Bulk Products / CDMO Results Year Change (Millions of Yen) • Seikagaku sales up on higher sales of bulk products, contract development and Net sales 27,384 +1,221 +4.7% manufacturing
Slide 8: Income for 3Q of FY2023 (Year-on-Year)
Exploring the Innovative Promise of Glycoscience Income for 3Q of FY2023(Year-on-Year) 3Q FY2023 Year-on- % of Operating Income 2,328 (-1,078) (Millions of Yen) Results Year Change Cost of sales ratio（+5.6 pt） Net sales 27,384 +1,221 +4.7% • Cost of sales ratio up because of change in the sales mix
Slide 9: Trend in R&D Expenses
Exploring the Innovative Promise of Glycoscience Trend in R&D Expenses Continuing to focus on drug discovery specializing in Glycoscience Undertaking improvement in R&D efficiency R&D Expenses Ratio to Net sales ● Ratio to Net sales(excluding royalty income) 30.0% 29.7% (Millions of Yen) 29.2% 28.3%
Slide 10: Pipeline List
Exploring the Innovative Promise of Glycoscience Pipeline List Development code/ Appli- Market Indication (Product name) PI PII PIII cation approval SI-6603 SI-6603 Lumbar Disk Herniation （Condoliase） US SI-614 SI-614 Dry eye US （Modified Hyaluronate） SI-613 SI-613 Target Market US：Knee Osteoarthrit
Slide 11: SI-6603 (Treatment for Lumbar Disc Herniation)
Exploring the Innovative Promise of Glycoscience SI-6603 (Treatment for Lumbar Disc Herniation) Received the results from a Phase III study in the U.S. Proceed with preparations for an application for approval Administration image Development status ▶ Phase III additional study in the U.S. SI-6603 •
Slide 12: SI-614 (Dry Eye)
Exploring the Innovative Promise of Glycoscience SI-614 (Dry Eye) Received the results from a Phase III study in the U.S. Currently considering the future development policy Development status Administration image ▶ Phase III study in the U.S. • Statistically significant improvement in the primary e
Slide 13: SI-722 (Interstitial cystitis and bladder pain syndrome)
Exploring the Innovative Promise of Glycoscience SI-722 (Interstitial cystitis and bladder pain syndrome) Subject enrollment for Phase I/II studies in the U.S. completed Currently considering the future development policy Administration image Development status ▶ Phase I/II studies in the U.S. ・Subj
Slide 14: SI-449 (Adhesion Barrier / Medical Device)
Exploring the Innovative Promise of Glycoscience SI-449 (Adhesion Barrier / Medical Device) Received the results from pivotal and pilot studies in Japan Proceed with preparations for an application for approval Development status Administration image ▶ Japan pivotal study (field of gastroenterologic
Slide 15: Basic Policy on Profit Distribution
Exploring the Innovative Promise of Glycoscience Basic Policy on Profit Distribution Make investments for sustained profit growth and corporate value enhancement and pay stable dividends Shareholder returns Consider dividend increases with ¥26 per share as a guideline, taking into account business p
Slide 16: Cautionary Notes
■Cautionary Notes This material contains forward-looking statements regarding future management strategies or performance forecasts. These descriptions are based on judgments derived from information that is currently available to Seikagaku and are subject to risk and uncertainty. Actual results and